Apimeds Pharmaceuticals US (APUS) vs Medicus Pharma (MDCX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Apimeds Pharmaceuticals US (APUS) has outperformed Medicus Pharma (MDCX) over the past year, losing 70.5% versus a loss of 95.9%. Apimeds Pharmaceuticals US is the larger company by market cap ($6.9 million vs $138,068), about 50.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APUS | MDCX |
|---|---|---|
| Share price | $4.58 | $0.0921 |
| Market cap | $6.90M | $138.07K |
| 1-day change | -16.97% | -9.62% |
| YTD return | -66.40% | -93.34% |
| 1-year return | -70.53% | -95.86% |
| EPS (TTM) | $-36.03 | $-119.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $59.70 | $139.00 |
| 52-week low | $1.51 | $0.084 |
| Distance from 52-week high | -92.34% | -99.93% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +4785.99% |
| Average volume | 3.67M | 92.96K |
| Shares outstanding | 1.51M | 1.50M |
| Employees | — | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Apimeds Pharmaceuticals US is about 50.0 times larger than Medicus Pharma by market value ($6.90M vs $138.07K).
- APUS has outperformed MDCX by 25.3 percentage points over the past year.
About Apimeds Pharmaceuticals US
APUS stock →Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure.
Health Care · Biotechnology: Pharmaceutical Preparations
About Medicus Pharma
MDCX stock →Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
APUS vs MDCX FAQ
Which is bigger, Apimeds Pharmaceuticals US or Medicus Pharma?
Apimeds Pharmaceuticals US (APUS) is larger, with a market capitalization of $6.90M compared with $138.07K for Medicus Pharma (MDCX).
Which stock has performed better over the past year, APUS or MDCX?
APUS returned -70.53% over the past 12 months, compared with -95.86% for MDCX (price return, excluding dividends). Past performance does not predict future results.
Are Apimeds Pharmaceuticals US and Medicus Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.